Eli Lilly and Company (NYSE:LLY) Shares Sold by Marietta Wealth Management LLC

Marietta Wealth Management LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,926 shares of the company’s stock after selling 481 shares during the quarter. Eli Lilly and Company comprises approximately 1.5% of Marietta Wealth Management LLC’s investment portfolio, making the stock its 18th largest holding. Marietta Wealth Management LLC’s holdings in Eli Lilly and Company were worth $8,701,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. Fairfield Bush & CO. purchased a new stake in Eli Lilly and Company in the first quarter valued at approximately $107,000. Roundview Capital LLC increased its stake in shares of Eli Lilly and Company by 2.6% in the first quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock worth $589,000 after acquiring an additional 53 shares during the period. Merit Financial Group LLC acquired a new stake in Eli Lilly and Company during the 1st quarter worth about $210,000. NewEdge Advisors LLC raised its stake in shares of Eli Lilly and Company by 9.9% during the 1st quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock valued at $15,193,000 after buying an additional 4,774 shares during the last quarter. Finally, Barometer Capital Management Inc. purchased a new stake in Eli Lilly and Company in the 1st quarter worth approximately $561,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 1.0 %

Shares of NYSE LLY traded down $7.54 during mid-day trading on Tuesday, reaching $743.23. The company had a trading volume of 1,067,986 shares, compared to its average volume of 3,065,144. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 52-week low of $367.35 and a 52-week high of $800.78. The stock has a market cap of $706.19 billion, a P/E ratio of 128.77, a PEG ratio of 1.65 and a beta of 0.34. The firm has a 50 day simple moving average of $762.68 and a two-hundred day simple moving average of $655.54.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s revenue was up 28.1% compared to the same quarter last year. During the same period in the prior year, the company earned $2.09 earnings per share. Sell-side analysts predict that Eli Lilly and Company will post 12.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on LLY. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Citigroup lifted their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $815.00 price target on shares of Eli Lilly and Company in a research report on Monday. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.